{"id":43718,"date":"2025-10-17T19:48:58","date_gmt":"2025-10-17T11:48:58","guid":{"rendered":"https:\/\/flcube.com\/?p=43718"},"modified":"2025-10-17T19:48:59","modified_gmt":"2025-10-17T11:48:59","slug":"aosaikangs-askgene-pharma-licenses-askg712-to-visara-for-macular-disease-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43718","title":{"rendered":"Aosaikang’s AskGene Pharma Licenses ASKG712 to Visara for Macular Disease Treatment"},"content":{"rendered":"\n

Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755<\/a>) announced on October 17, 2025, that its subsidiary, AskGene Pharma, Inc., has entered into a licensing agreement with Visara, Inc. The agreement grants Visara a paid license for ASKG712, a Class 1 innovative drug with independent intellectual property rights, within the licensed territory.<\/p>\n\n\n\n

ASKG712 Mechanism and Clinical Stage<\/strong>
ASKG712, developed by AskGene Pharma, is a dual-targetinnovative drug that simultaneously blocks the VEGF\/VEGFR signaling pathway and inhibits the ANG-2 signal. This action improves vascular stability and reduces retinal inflammation, targeting the treatment of macular diseases. Currently, ASKG712 is in Phase IIa clinical studies in China.<\/p>\n\n\n\n

Agreement Terms and Territory<\/strong>
Under the agreement, Visara will obtain exclusive rights to develop, manufacture, and commercialize ASKG712 within the licensed territory, which includes Greater China (Mainland China, Hong Kong SAR, Macau SAR, Taiwan), Singapore, Thailand, Malaysia, Indonesia, Vietnam, South Korea, and India. Visara will pay AskGene Pharma a one-time upfront payment of USD 7 million and additional milestone payments up to USD 89 million, along with tiered royalties based on annual net sales.-Fineline Info & Tech<\/a><\/p>\n\n\n\n